3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
307
Lung Neoplasms
111
Adenocarcinoma of Lung
23
Non-Squamous Non-Small Cell Lung Cancer
21
Neoplasms
21
Adenocarcinoma, Bronchiolo-Alveolar
15
Brain Neoplasms
14
Neoplasm Metastasis
10
Squamous Cell Carcinoma of Head and Neck
5
Respiratory Tract Diseases
5
Carcinoma
5
Breast Neoplasms
5
Adenocarcinoma
5
Thoracic Neoplasms
4
Recurrence
4
Pancreatic Neoplasms
4
NSCLC
4
Colorectal Neoplasms
4
Colonic Neoplasms
4
Salivary Gland Neoplasms
3
Respiratory Tract Neoplasms
3
Rectal Neoplasms
3
Lung Diseases
3
Esthesioneuroblastoma, Olfactory
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Thymoma
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Pleural Effusion, Malignant
2
Interventions
Docetaxel
6
Gemcitabine
3
Carboplatin
3
lorlatinib
2
cemiplimab
2
Vinorelbine
2
S 1 (combination)
2
Pemetrexed
2
Erlotinib Hydrochloride
2
Cisplatin
2
Cetuximab
2
zimberelimab
1
surufatinib
1
sintilimab
1
quemliclustat
1
pemigatinib
1
pembrolizumab
1
nimotuzumab
1
fludarabine
1
WW Domain-Containing Oxidoreductase
1
Paclitaxel
1
Interleukin-2
1
Gene Expression Profiling
1
Drug Therapy
1
Cyclophosphamide
1
Capecitabine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Advanced Non-Small Cell Lung Cancer
×
Erlotinib Hydrochloride
×
Thoracic
×
Clear all
NCT00349219
2016-01-15
TORCH
National Cancer Institute, Naples
Phase 3
Completed
760 enrolled
NCT00783471
2010-06-16
DOPERLO
Hellenic Cooperative Oncology Group
Phase 2
Terminated
51 enrolled